Capecitabine monotherapy: safe and effective treatment for metastatic breast cancer.
about
PARP inhibitors in the management of breast cancer: current data and future prospectsCombined inhibition of glycolysis and AMPK induces synergistic breast cancer cell killing.Prediction of cancer drugs by chemical-chemical interactionsThe patient-provider discordance in patients' needs assessment: a qualitative study in breast cancer patients receiving oral chemotherapy.Phase II study of oxaliplatin plus leucovorin and 5-fluorouracil in heavily pretreated metastatic breast cancer patients.Chemotherapy with low-dose capecitabine as palliative treatment in a patient with metastatic breast cancer: a case report.BP-C1 in the treatment of patients with stage IV breast cancer: a randomized, double-blind, placebo-controlled multicenter study and an additional open-label treatment phase.Neo-adjuvant capecitabine chemotherapy in women with newly diagnosed locally advanced breast cancer in a resource-poor setting (Nigeria): efficacy and safety in a phase II feasibility studyHealth-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trialManagement of hand-foot syndrome induced by capecitabine.A phase 3 tRial comparing capecitabinE in combination with SorafenIb or pLacebo for treatment of locally advanced or metastatIc HER2-Negative breast CancEr (the RESILIENCE study): study protocol for a randomized controlled trial.All-oral combination of oral vinorelbine and capecitabine as first-line chemotherapy in HER2-negative metastatic breast cancer: an International Phase II Trial.Utility of patient-derived lymphoblastoid cell lines as an ex vivo capecitabine sensitivity prediction model for breast cancer patients.Overcoming drug resistance in patients with metastatic breast cancer.Eribulin mesylate in pretreated breast cancer patients: a multicenter retrospective observational study.Breast cancer, DPYD mutations and capecitabine-related ileitis: description of two cases and a review of the literature.Pharmacogenetics of chemotherapy efficacy in breast cancer.Pharmacokinetic evaluation of capecitabine in breast cancer.Efficacy and safety of eribulin in taxane-refractory patients in the 'real world'.Eribulin mesylate: a promising new antineoplastic agent for locally advanced or metastatic breast cancer.Examination of the clinical usefulness of TS-1 in locally recurrent breast cancer.Gemcitabine and capecitabine in combination for advanced anthracycline and taxane pre-treated breast cancer patients: A phase II study.Capecitabine non-adherence: exploration of magnitude, nature and contributing factors.Fluorinated nucleosides as an important class of anticancer and antiviral agents.Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine.Gemcitabine-based chemotherapy as a viable option for treatment of advanced breast cancer patients: a meta-analysis and literature review.Germline pharmacogenomics of DPYD*9A (c.85T>C) variant in patients with gastrointestinal malignancies treated with fluoropyrimidines.Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxaneTreatment Options in Anthracycline and/or Taxane Pretreated Patients with Metastatic Breast Cancer
P2860
Q26798352-C64E5C1B-C2F7-460F-97C1-A9370552835CQ27317158-26B49173-209A-4494-8EA5-D31950D63F80Q28539449-DCB4D453-B8C2-40B4-8B11-691951A03E44Q30275892-D2B680F5-D183-46D4-88DA-6E35AE631F12Q33394017-763322E9-9306-4956-9A3E-91FE95D196A1Q33580239-9667B8BF-6668-478C-8806-54F951C4AB6FQ34609443-62643372-F62A-4305-981E-BD901CDD979BQ34806837-537DC417-4C4F-40A4-A9C6-40B510286530Q36322815-DC65931A-CAFD-4369-908D-113D0A9AD3D4Q36615314-220420C1-2D68-4EA0-B3B8-FDF39FAD6779Q37048596-3D011C37-CB68-4A82-AD2D-C057D257DD40Q37287394-119D9180-220B-44B2-880C-9663D5E60832Q37437491-CFCC4483-6990-4C28-8EA5-21F4F3F7681EQ37564485-C3C259A7-87A0-4013-94D1-8161960BA224Q37695495-E965A321-4AEA-4CD2-9ECB-29F601C3A08DQ37711732-099289B2-07D9-4DA7-B2CE-4C1CF66ACAB0Q38003703-79B15B22-BA4E-457D-9C05-BC8540FFC290Q38072718-F00C62A2-067B-4A6E-B0AB-DD22E81422B1Q38741802-6C049A66-D046-41F7-A000-6B40C08585DDQ39775442-E8D71597-EE65-4CD8-9A12-75B85B4BF192Q42197945-6C5E5D30-5ED3-443C-A9C9-109C2CCF5AFCQ43258971-472E072F-9E18-4108-93B5-ED8453A41147Q44141281-12E65334-7B56-4A0C-BECB-865E2FE03D5DQ47637142-EBA0233C-B397-4289-B22D-3AA8F6F3BD76Q48305630-E248674E-BECB-41F8-A954-ECC199437EADQ50221869-8CEBC02B-0816-4A22-A461-854E51126D23Q55668963-D050F9F3-B48E-4E89-BE4B-E427E667CAFDQ57222268-6EC184C6-57E6-4D9B-BE73-F0FA2A35283CQ57578932-4FBF9476-1CCA-4489-B16C-D649A9CD2FB3
P2860
Capecitabine monotherapy: safe and effective treatment for metastatic breast cancer.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Capecitabine monotherapy: safe and effective treatment for metastatic breast cancer.
@ast
Capecitabine monotherapy: safe and effective treatment for metastatic breast cancer.
@en
type
label
Capecitabine monotherapy: safe and effective treatment for metastatic breast cancer.
@ast
Capecitabine monotherapy: safe and effective treatment for metastatic breast cancer.
@en
prefLabel
Capecitabine monotherapy: safe and effective treatment for metastatic breast cancer.
@ast
Capecitabine monotherapy: safe and effective treatment for metastatic breast cancer.
@en
P1433
P1476
Capecitabine monotherapy: safe and effective treatment for metastatic breast cancer.
@en
P2093
William B Ershler
P304
P356
10.1634/THEONCOLOGIST.11-4-325
P577
2006-04-01T00:00:00Z